Bausch + Lomb Sale Process Gains Momentum As TPG And Blackstone Join Forces
Bausch + Lomb Sale Process Gains Momentum As TPG And Blackstone Join Forces
The Bausch + Lomb spin-off was part of Bausch Health's plan to alleviate its $21 billion debt, a third of which is due by 2027.Private equity firms TPG and Blackstone are joining forces in a bid to acquire eye care company Bausch + Lomb (NYSE:BLCO), the Financial Times reported.
据《金融时报》报道，私募股权公司TPG和黑石集团正在联手收购眼部护理公司Bausch + Lomb（纽约证券交易所代码：BLCO）。
Last month, Bausch + Lomb said it was considering a sale.
上个月，Bausch + Lomb表示正在考虑出售。
The auction is part of an effort to address concerns from creditors, including Apollo Global Management Inc (NYSE:APO), over the separation from parent company, Bausch Health Companies (NYSE:BHC)..
此次拍卖是解决包括阿波罗环球管理公司（纽约证券交易所代码：APO）在内的债权人对与母公司鲍什健康公司（纽约证券交易所代码：BHC）分离的担忧的一部分。
The Bausch + Lomb spin-off was part of Bausch Health's plan to alleviate its $21 billion debt, a third of which is due by 2027.
Bausch + Lomb的分拆是Bausch Health减免其210亿美元债务计划的一部分，其中三分之一将在2027年到期。
If TPG and Blackstone are successful, the deal could rank among the largest private equity buyouts of the year. Bausch + Lomb's enterprise value, including debt, amounts to $11.5 billion.
如果TPG和黑石集团成功，这笔交易可能成为本年度最大的私募股权收购之一。Bausch + Lomb的企业价值，包括债务，为115亿美元。
Other potential bidders are no longer in the running, positioning TPG and Blackstone as the front-runners.
其他潜在的竞标者已不再竞选，他们将TPG和黑石集团定位为领跑者。
The acquisition process is expected to value Bausch + Lomb at $13 billion to $14 billion, translating to a per-share price of up to $25.
收购过程预计将使Bausch + Lomb的估值达到130亿美元至140亿美元，相当于每股价格高达25美元。
Goldman Sachs is leading the sale process to end a feud between Bausch Health's shareholders and creditors.
高盛正在领导出售过程，以结束Bausch Health股东与债权人之间的争执。
Bausch + Lomb CEO Brent Saunders orchestrated Allergan's $63 billion sale to AbbVie Inc (NYSE:ABBV). Formal bids are expected by the end of the month, though no deal is guaranteed.
Bausch + Lomb首席执行官布伦特·桑德斯策划了Allergan向艾伯维公司（纽约证券交易所代码：ABBV）630亿美元的出售。尽管无法保证达成协议，但预计将在本月底之前进行正式竞标。
Bausch Health's top shareholders, including Carl Icahn and John Paulson's Paulson & Co., had supported the spin-off, seeing potential benefits in owning a larger share of the more profitable eye care subsidiary.
Bausch Health的最大股东，包括卡尔·伊坎和约翰·保尔森旗下的保尔森公司，都支持分拆业务，他们认为拥有利润更高的眼科护理子公司的更大份额可能带来好处。
Bausch Health currently faces challenges with its leading drug, Xifaxan, which will lose patent protection by 2029.
Bausch Health目前面临着其领先药物Xifaxan的挑战，该药物到2029年将失去专利保护。
Price Action: Bausch + Lomb stock is up 10.7% at $21.55 during the premarket session at last check Monday.
价格走势：周一最后一次盘前交易中，Bausch + Lomb股价上涨10.7％，至21.55美元。
- GM Strikes Deal With Barclays To Supercharge Its Rewards Mastercard Program.
- 通用汽车与巴克莱达成协议，以增强其万事达卡奖励计划。
Image: Shutterstock
图片：Shutterstock
